EUVIMEDEUVIMED entdecken
Open Access

Preclinical verification of the efficacy by targeting peptide-linked liposomal nanoparticles for hepatocellular carcinoma therapy

Cheng-Der Wu, Jen-Chieh Lee, Hang-Chung Wu, Chung-Wei Lee, Chih-Feng Lin, Ming-Chen Hsu, Chin-Tarng Lin iD

Nanobiomedicine · 2019

DOI: 10.1177/1849543519880762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanobiomedicine, 2019. Verfasst von Cheng-Der Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute and Department of Pathology, National Taiwan University Hospital, Taipei, Republic of China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Taiwan National Science and Technology Development Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of this study was to investigate the efficacy of targeting peptides chemotherapy to overcome adverse event in the conventional chemotherapy for human hepatocellular carcinoma. Previously we reported several cancer-targeting peptides that bind specifically to cancer cells and their vascular endothelia: L-peptide (anti-cancer cell membrane), RLLDTNRPLLPY; SP-94-peptide (anti-hepatoma cell membrane), SFSHHTPILP; PC5-52-peptide (anti-tumor endothelia), SVSVGMKPSPRP; and control peptide, RLLDTNRGGGGG. In this study, these peptides were linked to liposomal iron oxide nanoparticles to localize the targeted tumor cells and endothelia, and to dextran-coated liposomal doxorubicin (L-D) to treat nonobese diabetic severe combined immunodeficient mice bearing hepatoma xenografts. Our results showed that L-peptide-linked liposomal doxorubicin could inhibit tumor growth with very mild adverse events. Use of the control peptide led to a decrease in the xenograft size but also led to marked apoptotic change in the visceral organ. In conclusion, L-peptide-linked liposomal doxorubicin, SP-94-peptide, and PC5-52-peptide can be used for the treatment of hepatoma xenografts in nonobese diabetic severe combined immunodeficient mice with minimal adverse events.

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinomaL-peptidePC5-52-peptideSP-94-peptidepeptide-targeted chemotherapy

Autor:innen und Institutionen

  • Institute and Department of Pathology, National Taiwan University Hospital, Taipei, Republic of China.
  • Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Republic of China.
  • Department of Medical Imaging and Radiology, National Taiwan University Hospital, Taipei, Republic of China.
  • Department of Otolaryngology, National Taiwan University Hospital, Taipei, Republic of China.

ORCID-Profile: Chin-Tarng Lin

Förderung

  • Taiwan National Science and Technology Development Agency

Zitieren

APA

Wu, C. D., Lee, J. C., Wu, H. C., Lee, C. W., Lin, C. F., Hsu, M. C., & Lin, C. T. (2019). Preclinical verification of the efficacy by targeting peptide-linked liposomal nanoparticles for hepatocellular carcinoma therapy. Nanobiomedicine. https://doi.org/10.1177/1849543519880762

Vancouver

Wu CD, Lee JC, Wu HC, Lee CW, Lin CF, Hsu MC, et al. Preclinical verification of the efficacy by targeting peptide-linked liposomal nanoparticles for hepatocellular carcinoma therapy. Nanobiomedicine. 2019. doi:10.1177/1849543519880762

BibTeX
@article{Wu2019,
  author = {Wu, Cheng-Der and Lee, Jen-Chieh and Wu, Hang-Chung and Lee, Chung-Wei and Lin, Chih-Feng and Hsu, Ming-Chen and Lin, Chin-Tarng},
  title = {Preclinical verification of the efficacy by targeting peptide-linked liposomal nanoparticles for hepatocellular carcinoma therapy},
  journal = {Nanobiomedicine},
  year = {2019},
  doi = {10.1177/1849543519880762}
}
Kostenlos starten →